NEW YORK (GenomeWeb) – Natural Molecular Testing, currently in Chapter 11 reorganization, has reached a settlement with the Centers for Medicare and Medicaid Services to pay back the agency $71.1 million in overpayments received by NMT. 

In court documents filed on Thursday in US Bankruptcy Court, Western District of Washington at Seattle, the trustee for NMT said the firm will cease all operations, end its plans to reorganize, and liquidate its assets. 

Under the terms of the settlement, NMT will begin repaying CMS after it has paid other creditors $1 million. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Oct
02
Sponsored by
Roche

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.

Oct
11
Sponsored by
ArcherDX

This webinar will discuss a validation study for a next-generation sequencing (NGS) assay for hematological malignancies (e.g., acute myeloid leukemia, acute lymphocytic leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms).

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.